Intranasal prophylaxis with cpg oligodeoxynucleotide can protect against yersinia pestis infection

Infection and Immunity

Volumn 81, Issue 6, 2013, Pages 2123-2132

  Hickey, Anthony J ^a   Lin, Jr Shiuan ^a   Kummer, Lawrence W ^a   Szaba, Frank M ^a   Duso, Debra K ^a   Tighe, Michael ^a   Parent, Michelle A ^a,b   Smiley, Stephen T ^a  

^a TRUDEAU INSTITUTE   (United States)

^b UNIVERSITY OF DELAWARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BACTERIAL GROWTH; BACTERIAL LOAD; CONTROLLED STUDY; INFECTION PREVENTION; LIVER; LONG TERM SURVIVAL; LUNG; MOUSE; NONHUMAN; PLAGUE; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; GENE EXPRESSION REGULATION; LIVER; LUNG; MICE; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; PLAGUE; SPECIFIC PATHOGEN-FREE ORGANISMS; TOLL-LIKE RECEPTOR 9; VIRULENCE; YERSINIA PESTIS;

EID: 84877830638     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00316-13     Document Type: Article

References (64)

1. Perry RD, Fetherston JD. 1997. Yersinia pestis-etiologic agent of plague. Clin. Microbiol. Rev. 10:35-66.
2. Pollitzer R. 1954. Plague. Monogr. Ser. World Health Organ. 22:1-698.
3. Prentice MB, Rahalison L. 2007. Plague. Lancet 369:1196-1207.
4. Butler T. 1983. Plague and other Yersinia infections. Plenum Press, New York, NY.
5. Sebbane F, Jarrett CO, Gardner D, Long D, Hinnebusch BJ. 2006. Role of the Yersinia pestis plasminogen activator in the incidence of distinct septicemic and bubonic forms of flea-borne plague. Proc. Natl. Acad. Sci. U. S. A. 103:5526-5530.
6. Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Koerner JF, Layton M, McDade J, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Schoch-Spana M, Tonat K. 2000. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 283:2281-2290.
7. Kool JL. 2005. Risk of person-to-person transmission of pneumonic plague. Clin. Infect. Dis. 40:1166-1172.
8. Smiley ST. 2008. Current challenges in the development of vaccines for pneumonic plague. Expert Rev. Vaccines 7:209-221.
9. Smiley ST. 2008. Immune defense against pneumonic plague. Immunol. Rev. 225:256-271.
10. Ratsitorahina M, Chanteau S, Rahalison L, Ratsifasoamanana L, Boisier P. 2000. Epidemiological and diagnostic aspects of the outbreak of pneumonic plague in Madagascar. Lancet 355:111-113.
11. Titball RW, Williamson ED. 2004. Yersinia pestis (plague) vaccines. Expert Opin. Biol. Ther. 4:965-973.
12. Williamson ED, Packer PJ, Waters EL, Simpson AJ, Dyer D, Hartings J, Twenhafel N, Pitt ML. 2011. Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague. Vaccine 29:4771-4777.
13. Hart MK, Saviolakis GA, Welkos SL, House RV. 2012. Advanced development of the rF1V and rBV A/B vaccines: progress and challenges. Adv. Prev. Med. 2012:731604.
14. Pitt M. 2004. Non-human primates as a model for pneumonic plague. Animals Models and Correlates of Protection for Plague Vaccines Workshop, Gaithersburg, MD, 13 to 14 October 2004.
15. Cornelis GR. 2002. Yersinia type III secretion: send in the effectors. J. Cell Biol. 158:401-408.
16. Viboud GI, Bliska JB. 2005. Yersinia outer proteins: role in modulation of host cell signaling responses and pathogenesis. Annu. Rev. Microbiol. 59: 69-89.
17. Heesemann J, Sing A, Trulzsch K. 2006. Yersinia's stratagem: targeting innate and adaptive immune defense. Curr. Opin. Microbiol. 9:55-61.
18. Montminy SW, Khan N, McGrath S, Walkowicz MJ, Sharp F, Conlon JE, Fukase K, Kusumoto S, Sweet C, Miyake K, Akira S, Cotter RJ, Goguen JD, Lien E. 2006. Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response. Nat. Immunol. 7:1066-1073.
19. Kawahara K, Tsukano H, Watanabe H, Lindner B, Matsuura M. 2002. Modification of the structure and activity of lipid A in Yersinia pestis lipopolysaccharide by growth temperature. Infect. Immun. 70:4092-4098.
20. Rebeil R, Ernst RK, Gowen BB, Miller SI, Hinnebusch BJ. 2004. Variation in lipid A structure in the pathogenic yersiniae. Mol. Microbiol. 52:1363-1373.
21. Szaba FM, Kummer LW, Wilhelm LB, Lin JS, Parent MA, Montminy-Paquette SW, Lien E, Johnson LL, Smiley ST. 2009. D27-pLpxL, an avirulent strain of Yersinia pestis, primes T cells that protect against pneumonic plague. Infect. Immun. 77:4295-4304.
22. Airhart CL, Rohde HN, Bohach GA, Hovde CJ, Deobald CF, Lee SS, Minnich SA. 2008. Induction of innate immunity by lipid A mimetics increases survival from pneumonic plague. Microbiology 154:2131-2138.
23. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, Wagner H, Lipford GB. 2001. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. Sci. U. S. A. 98:9237-9242.
24. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546-549.
25. Deng JC, Moore TA, Newstead MW, Zeng X, Krieg AM, Standiford TJ. 2004. CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection. J. Immunol. 173:5148-5155.
26. Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas ZK, Endres S, Krieg AM, Hartmann G. 2001. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur. J. Immunol. 31:2154-2163.
27. Ballas ZK, Krieg AM, Warren T, Rasmussen W, Davis HL, Wald-schmidt M, Weiner GJ. 2001. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J. Immunol. 167:4878-4886.
28. Elkins KL, Rhinehart-Jones TR, Stibitz S, Conover JS, Klinman DM. 1999. Bacterial DNA containing CpG motifs stimulates lymphocytedependent protection of mice against lethal infection with intracellular bacteria. J. Immunol. 162:2291-2298.
29. Klinman DM. 2004. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4:249-258.
30. Judy BM, Taylor K, Deeraksa A, Johnston RK, Endsley JJ, Vijayakumar S, Aronson JF, Estes DM, Torres AG. 2012. Prophylactic application of CpG oligonucleotides augments the early host response and confers protection in acute melioidosis. PLoS One 7:e34176. doi:10.1371/journal .pone.0034176.
31. Easton A, Haque A, Chu K, Patel N, Lukaszewski RA, Krieg AM, Titball RW, Bancroft GJ. 2011. Combining vaccination and postexposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis. J. Infect. Dis. 204:636-644.
32. Waag DM, McCluskie MJ, Zhang N, Krieg AM. 2006. A CpG oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei. Infect. Immun. 74:1944-1948.
33. Wongratanacheewin S, Kespichayawattana W, Intachote P, Pichyangkul S, Sermswan RW, Krieg AM, Sirisinha S. 2004. Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei. Infect. Immun. 72:4494-4502.
34. Wong CE, Sad S, Coombes BK. 2009. Salmonella enterica serovar Typhimurium exploits Toll-like receptor signaling during the host-pathogen interaction. Infect. Immun. 77:4750-4760.
35. Lathem WW, Crosby SD, Miller VL, Goldman WE. 2005. Progression of primary pneumonic plague: a mouse model of infection, pathology, and bacterial transcriptional activity. Proc. Natl. Acad. Sci. U. S. A. 102:17786-17791.
36. Lee-Lewis H, Anderson DM. 2010. Absence of inflammation and pneumonia during infection with nonpigmented Yersinia pestis reveals a new role for the pgm locus in pathogenesis. Infect. Immun. 78:220-230.
37. Lahteenmaki K, Virkola R, Saren A, Emody L, Korhonen TK. 1998. Expression of plasminogen activator pla of Yersinia pestis enhances bacterial attachment to the mammalian extracellular matrix. Infect. Immun. 66:5755-5762.
38. Parent MA, Berggren KN, Kummer LW, Wilhelm LB, Szaba FM, Mullarky IK, Smiley ST. 2005. Cell-mediated protection against pulmonary Yersinia pestis infection. Infect. Immun. 73:7304-7310.
39. Jakob T, Walker PS, Krieg AM, von Stebut E, Udey MC, Vogel JC. 1999. Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses. Int. Arch. Allergy Immunol. 118:457-461.
40. Parent MA, Wilhelm LB, Kummer LW, Szaba FM, Mullarky IK, Smiley ST. 2006.Gammainterferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection. Infect. Immun. 74:3381-3386.
41. Hall JD, Woolard MD, Gunn BM, Craven RR, Taft-Benz S, Frelinger JA, Kawula TH. 2008. Infected-host-cell repertoire and cellular response in the lung following inhalation of Francisella tularensis Schu S4, LVS, or U112. Infect. Immun. 76:5843-5852.
42. Patel AA, Lee-Lewis H, Hughes-Hanks J, Lewis CA, Anderson DM. 2012. Opposing roles for interferon regulatory factor-3 (IRF-3) and type I interferon signaling during plague. PLoS Pathog. 8:e1002817. doi:10.1371 /journal.ppat.1002817.
43. Bendigs S, Salzer U, Lipford GB, Wagner H, Heeg K. 1999. CpGoligodeoxynucleotides co-stimulate primary T cells in the absence of antigen-presenting cells. Eur. J. Immunol. 29:1209-1218.
44. Anderson GW, Jr, Worsham PL, Bolt CR, Andrews GP, Welkos SL, Friedlander AM, Burans JP. 1997. Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis. Am. J. Trop. Med. Hyg. 56:471-473.
45. Eisele NA, Anderson DM. 2009. Dual-function antibodies to Yersinia pestis LcrV required for pulmonary clearance of plague. Clin. Vaccine Immunol. 16:1720-1727.
46. Green M, Rogers D, Russell P, Stagg AJ, Bell DL, Eley SM, Titball RW, Williamson ED. 1999. The SCID/Beige mouse as a model to investigate protection against Yersinia pestis. FEMS Immunol. Med. Microbiol. 23: 107-113.
47. Hill J, Copse C, Leary S, Stagg AJ, Williamson ED, Titball RW. 2003. Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis. Infect. Immun. 71: 2234-2238.
48. Hill J, Eyles JE, Elvin SJ, Healey GD, Lukaszewski RA, Titball RW. 2006. Administration of antibody to the lung protects mice against pneumonic plague. Infect. Immun. 74:3068-3070.
49. Motin VL, Nakajima R, Smirnov GB, Brubaker RR. 1994. Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide. Infect. Immun. 62:4192-4201.
50. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408:740-745.
51. Takeshita F, Leifer CA, Gursel I, Ishii KJ, Takeshita S, Gursel M, Klinman DM. 2001. Cutting edge: role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J. Immunol. 167:3555-3558.
52. Tasaka S, Kamata H, Miyamoto K, Nakano Y, Shinoda H, Kimizuka Y, Fujiwara H, Hasegawa N, Fujishima S, Miyasho T, Ishizaka A. 2009. Intratracheal synthetic CpG oligodeoxynucleotide causes acute lung injury with systemic inflammatory response. Respir. Res. 10:84.
53. Pesce I, Monaci E, Muzzi A, Tritto E, Tavarini S, Nuti S, De Gregorio E, Wack A. 2010. Intranasal administration of CpG induces a rapid and transient cytokine response followed by dendritic and natural killer cell activation and recruitment in the mouse lung. J. Innate Immun. 2:144-159.
54. Philipovskiy AV, Smiley ST. 2007. Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection. Infect. Immun. 75:878-885.
55. Lin JS, Kummer LW, Szaba FM, Smiley ST. 2011. IL-17 contributes to cell-mediated defense against pulmonary Yersinia pestis infection. J. Immunol. 186:1675-1684.
56. Chattopadhyay A, Park S, Delmas G, Suresh R, Senina S, Perlin DS, Rose JK. 2008. Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection. Vaccine 26:6329-6337.
57. Levy Y, Flashner Y, Tidhar A, Zauberman A, Aftalion M, Lazar S, Gur D, Shafferman A, Mamroud E. 2011. T cells play an essential role in anti-F1 mediated rapid protection against bubonic plague. Vaccine 29: 6866-6873.
58. Wang S, Goguen JD, Li F, Lu S. 2011. Involvement of CD8+ T cellmediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge. Vaccine 29:6802-6809.
59. Rozak DA, Gelhaus HC, Smith M, Zadeh M, Huzella L, Waag D, Adamovicz JJ. 2010. CpG oligodeoxyribonucleotides protect mice from Burkholderia pseudomallei but not Francisella tularensis Schu S4 aerosols. J. Immune Based Ther. Vaccines 8:2.
60. Pujol C, Bliska JB. 2003. The ability to replicate in macrophages is conserved between Yersinia pestis and Yersinia pseudotuberculosis. Infect. Immun. 71:5892-5899.
61. O'Loughlin JL, Spinner JL, Minnich SA, Kobayashi SD. 2010. Yersinia pestis two-component gene regulatory systems promote survival in human neutrophils. Infect. Immun. 78:773-782.
62. Noel BL, Lilo S, Capurso D, Hill J, Bliska JB. 2009. Yersinia pestis can bypass protective antibodies to LcrV and activation with gamma interferon to survive and induce apoptosis in murine macrophages. Clin. Vaccine Immunol. 16:1457-1466.
63. Straley SC, Harmon PA. 1984. Yersinia pestis grows within phagolysosomes in mouse peritoneal macrophages. Infect. Immun. 45:655-659.
64. Puangpetch A, Anderson R, Huang YY, Sermswan RW, Chaicumpa W, Sirisinha S, Wongratanacheewin S. 2012. Cationic liposomes extend the immunostimulatory effect of CpG oligodeoxynucleotide against Burkholderia pseudomallei infection in BALB/c mice. Clin. Vaccine Immunol. 19:675-683.